SARS-CoV-2-IN-36
SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells.
For research use only. We do not sell to patients.
- Formula: C17H21N5O3
- Molecular Weight:343.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
SARS-CoV-2-IN-36 (compound 58) inhibit the replication of the Wuhan (UC-1074),South African (RG2674), and UK (NVDBB-2220) SARS-CoV-2 variants, with IC50 values of 5.0 μM, 39.9 μM, and 5.2 μM, respectively. SARS-CoV-2-IN-36 alters cell morphology only at concentrations above ≥100 μM and does not inhibit Vero cell growth up to a concentration >100 μM[1].
SARS-CoV-2-IN-36 (compound 58) lacks antiviral activity against two herpesviruses (varicella-zoster virus and human cytomegalovirus) in human embryonic lung fibroblasts. SARS-CoV-2-IN-36 shows a very low cytotoxicity also against embryonic lung fibroblasts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
| Route | Dose (mg/kg) | Concentration (mg/mL) | Number of animals | Cmax (ng/mL) | Tmax (h) | AUCt/dose (h*kg*ng/mL/mg) |
| IN | 0.5 | 1.0 | 3 | 177.97±26.15 | 0.25±0.00 | 188.05±32.52 |
| IN | 1.25 | 2.5 | 3 | 325.95±42.45 | 0.25±0.00 | 150.62±23.80 |
| PO | 10 | 10 | 3 | 22.72±4.42 | 0.75±0.43 | 3.07±0.92 |
| PO | 25 | 2.5 | 3 | 33.67±3.42 | 0.5±0.43 | 2.00±0.51 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 343.38
-
Formula C17H21N5O3
-
SMILES
[H]C(C(N[C@H](C(N[C@@H](CC1=CNC=N1)C=O)=O)CC2=CC=CC=C2)=O)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)